 Connection
Ritsuko Iwanaga to Neoplasms
This is a "connection" page, showing publications Ritsuko Iwanaga has written about Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.301 |
|
|
|
-
Zhou Y, Nakajima R, Shirasawa M, Fikriyanti M, Watanabe A, Yang C, Iwanaga R, Bradford AP, Kurayoshi K, Araki K, Ohtani K. Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. Cells. 2026 Jan 05; 15(1).
Score: 0.080
-
Kurayoshi K, Tanaka M, Nakajima R, Zhou Y, Shirasawa M, Fikriyanti M, Fujisawa JI, Iwanaga R, Bradford AP, Araki K, Ohtani K. Utility of Tumor Suppressor E2F Target Gene Promoter Elements to Drive Gene Expression Specifically in Cancer Cells. Cells. 2025 Dec 09; 14(24).
Score: 0.079
-
Brubaker LW, Backos DS, Nguyen VT, Reigan P, Yamamoto TM, Woodruff ER, Iwanaga R, Wempe MF, Kumar V, Persenaire C, Watson ZL, Bitler BG. Novel chromobox 2 inhibitory peptide decreases tumor progression. Expert Opin Ther Targets. 2023 Apr-May; 27(4-5):361-371.
Score: 0.067
-
Nakajima R, Zhao L, Zhou Y, Shirasawa M, Uchida A, Murakawa H, Fikriyanti M, Iwanaga R, Bradford AP, Araki K, Warita T, Ohtani K. Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool. Genes (Basel). 2023 02 02; 14(2).
Score: 0.065
-
Kurayoshi K, Shiromoto A, Ozono E, Iwanaga R, Bradford AP, Araki K, Ohtani K. Ectopic expression of the CDK inhibitor p21Cip1 enhances deregulated E2F activity and increases cancer cell-specific cytotoxic gene expression mediated by the ARF tumor suppressor promoter. Biochem Biophys Res Commun. 2017 01 29; 483(1):107-114.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|